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Mortality and cancer from chemical weapons testing
Risk is not increased, but some health questions remain 
The experimental studies of the effects of chemical war-
fare agents conducted on thousands of British military 
personnel over several decades at the Porton Down 
facility in the United Kingdom have been an ongoing 
source of controversy regarding the scientific, ethical, 
and moral environment in which they took place.1 Con-
cerns about effects on health increased following a coro-
ner’s finding in 2004 of unlawful killing regarding the 
death of a Porton Down subject in 1953 after cutaneous 
administration of a chemical warfare nerve agent in a 
non-therapeutic experiment. This finding understand-
ably raised important questions about the longer term 
health of the 18 000 British veterans who took part in 
the Porton Down experiments.2 To investigate this, two 
linked studies have assessed whether the risks of cancer 
or mortality are higher in veterans who took part in tests 
compared with those who did not.3 4 
Established in 1916 in response to the use of chemi-
cal warfare agents against British troops in the first 
world war, the Porton Down facility was later expanded 
because of the threat posed by Germany during the sec-
ond world war; the use of chemical weapons by Iraq; 
and the later attacks by terrorists against civilians, such 
as the release of sarin in a subway in Tokyo in 1995. In 
response to increasing public concern, the UK Ministry 
of Defence commissioned an epidemiological study to 
investigate a range of health outcomes in the military 
personnel who took part in the Porton Down chemical 
weapon experiments. 
More than half of the Porton Down veterans were 
exposed to known or probable human carcinogens, 
most commonly dermal exposure to sulphur mustard,5 
so  Carpenter and colleagues’ study on cancer  morbidity 
is of considerable scientific and public interest. The 
authors found no significant differences in the overall 
incidence of cancer nor in the incidence of most cancer 
types in Porton Down veterans compared with non-
veterans.3 Although a few subgroups had some isolated 
excesses of specific cancer types—such as excess of can-
cer of the trachea, bronchus, and lung in Porton Down 
veterans exposed to Lewisite—the lack of smoking data 
and the large number of analyses make it difficult to 
draw any firm conclusions about the causal nature of 
these few findings.
Venables and colleagues’ study of mortality reported 
a small excess of overall mortality in the Porton Down 
veteran group.4 However, this overall excess was mainly 
the result of excesses in non-cancer causes of death, 
such as deaths from infectious and parasitic diseases, 
circulatory diseases, genitourinary causes, and exter-
nal causes. Some of these excess deaths are probably 
related to the longer period of service of Porton Down 
veterans compared with that of the comparison veteran 
group in the study, rather than to their involvement in 
the Porton Down experiments. Importantly, the authors 
found no increase in cancer mortality, consistent with 
the main finding in the cancer morbidity paper.3
The authors acknowledge that their studies have some 
limitations. Because UK cancer data have been available 
only since 1971, cancer rates in the early years of the 
Porton Down programme could not be studied. Also, 
it was not possible to adjust their findings for impor-
tant confounders, such as cigarette smoking. One of the 
major strengths of these studies was the painstaking and 
time consuming attention to detail in the assessment of 
exposure, which is not easy when extracting data from 
records that are several decades old.6
The overall findings are consistent with other studies 
of veterans with short term or intermittent exposure to 
chemical weapons. These include the study of US navy 
veterans from the second world war, who participated in 
mustard gas chamber tests, which found no excess in any 
cause specific mortality.7 Also, the mortality study of US 
army Gulf war veterans who were potentially exposed to 
nerve agents during the March 1991 chemical weapons 
demolition at Khamisiyah in Iraq, reported no significant 
findings, apart from a borderline excess of deaths from 
brain tumours.8
The findings of the two studies should provide some 
reassurance to Porton Down veterans and their sup-
porters that they have no excess risk of cancer or major 
causes of death. Although human carcinogens such as 
sulphur mustard and benzene were used in the Porton 
Down experiments, it should be remembered that the 
level and duration of exposure are important determi-
nants of future cancer risk. In this study, the veterans took 
part in the experiments for only one to four weeks, for 
an average of two days a week. Therefore, the cumula-
tive doses received were probably small compared with 
industrial exposure in manufacturing facilities, and—as 
the studies found—too low to cause a measurable excess 
of cancer.
Although these findings are reassuring for  cancer 
and mortality outcomes, we need to take a more  global 
view of the health of Porton Down subjects. This 
research group has previously published results for 
some other outcomes, which—although they have some 
 methodological limitations—showed excess reporting 
of symptoms and poorer quality of life in a subgroup 
of Porton Down veterans.9 The finding of excess symp-
ke
ys
to
n
e/
st
Ri
n
g
eR
/g
et
ty
 im
ag
es
ReseaRch, pp 749, 754 
Malcolm R sim director, monash 
Centre for occupational and 
environmental Health, school 
of Public Health and Preventive 
medicine, monash University, 
melbourne, ViC 3004, australia 
malcolm.sim@med.monash.edu.au
competing interests: none 
declared.
Provenance and peer review: 
Commissioned; not externally peer 
reviewed. 
Cite this as: BMJ 2009;338:b358
doi: 10.1136/bmj.b358
eDITORIaLsEditorials represent the opinions of the authors and not  necessarily those of the BMJ or BMA
For the full versions of these articles see bmj.com
726   BMJ | 28 March 2009 | VoluMe 338
eDITORIaLs
Treatment of depression in primary care
incentivised care is no substitute for professional judgment
Patients with chronic depression commonly present to 
general practice,1 and they often have other important 
(physical) diseases.2 Although effective treatment is avail-
able, evidence suggests that patients and practitioners 
make insufficient use of it.3 These are important reasons 
to improve general practitioners’ care of depression, as 
pursued by the World Health Organization action to inte-
grate mental health into primary care.4 In England and 
Scotland, the quality and outcomes framework (QOF) 
identifies evidence based interventions and provides 
financial incentives to practices that implement these 
interventions. This exciting and innovative approach to 
improving performance is followed with interest outside 
the United Kingdom.
Two linked studies look at the QOF system and the 
management of depression in primary care. Kendrick 
and colleagues assess whether rates of prescribing anti-
depressant drugs and referrals to specialist services vary 
according to patients’ scores on incentivised depres-
sion questionnaires.5 Validated screening instruments 
to assess the severity of depression include the hospital 
anxiety and depression score, the Beck depression inven-
tory, and the patients’ health questionnaire. Kendrick 
and colleagues report that practitioners usually adminis-
tered these questionnaires, but that some patients whose 
scores qualified them for treatment did not receive anti-
depressants or referral to specialised services—notably 
elderly patients and those with comorbidity. In addition, 
two of the questionnaires gave very different severity 
grades—83.5% of patients were classified as moderately 
to severely depressed and in need of treatment by the 
patients’ health questionnaire, whereas only 55.6% were 
classified as such by the hospital anxiety and depres-
sion score. This difference casts doubt on the validity of 
these scales and their usefulness in general practice. At 
first sight these results suggest that  the QOF approach 
may not be as useful as hoped in this situation, but it 
is important to understand the other factors that come 
into play.
The first of these factors is the nature of the interven-
tion. Prescription of antidepressants and referral to spe-
cialised services are “procedural” aspects of performance. 
Evidence based criteria can be applied to prescribing and 
referral, but successful care of patients with depression 
is determined by a combination of correct clinical pro-
cedures and a trusting doctor-patient relationship.6 This 
shifts the focus from treating just symptoms to treating 
the patient as a whole. The general practitioners in this 
study may therefore have opted to forfeit the incentives 
and work personally with their patient, rather than refer 
or prescribe. This is especially likely because many of 
the practices had a special interest in mental health, and 
because the number of follow-up appointments increased 
with the severity of depression. The second linked study 
by Dowrick and colleagues, which assessed how gen-
eral practitioners and patients valued questionnaires, 
confirms the importance of a holistic patient centred 
approach.7 
The surprise finding that older patients and those with 
comorbidity were less likely to be treated for depres-
sion brings us to the second factor. Intuitively, we would 
expect these patients to receive intervention more rather 
than less often. But comorbidity is as common as it is 
poorly investigated. General practitioners rely to a large 
extent on their clinical judgment, and they may be 
 reluctant to prescribe antidepressants because of  potential 
interactions with other drugs.8 Generic  interventions 
such as empowerment and lifestyle changes may be 
more attractive because they may treat more than one 
condition at the same time.9 Given the limited research, 
this is an area where general practitioners’ experience 
is well ahead of scientific evidence. Exploration of this 
 experience could further improve the QOF process.
Validated questionnaires can assess the severity of 
depression, but Kendrick and colleagues show that they 
were less robust than expected. In their qualitative inter-
view study, Dowrick and  colleagues show that patients 
appreciated the use of these questionnaires.7 It would be 
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toms has some similarities with reported effects in many 
other veteran groups after deployment to areas of high 
personal threat.10 Although the nature of the threat to 
Porton Down veterans was different from that experi-
enced by other veterans, non-fatal and non-cancer health 
outcomes in Porton Down veterans remain an important 
area of future research and public interest.
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interesting to know if this was the questionnaire as such 
or the explicit unambiguous questions asked about their 
condition, which could easily be incorporated into the 
general practitioner’s history taking. General practition-
ers were at best ambivalent about the questionnaire, and 
they often used their professional judgment rather than 
the results of the questionnaire to guide management. 
Again, it would be interesting to know if this was related 
to the nature of the questionnaires or the fact that they 
were less robust than had been assumed. The hospital 
anxiety and depression score for instance is designed 
to identify possible depression but further assessment 
is needed to confirm the diagnosis. This confirmation 
could possibly come from the general practitioners’ pro-
fessional judgment.
General practitioners prescribe treatment that is not 
always in accordance with guidelines or with the QOF 
system. These studies provide evidence that patients’ 
needs are better assessed by general practitioners’ pro-
fessional judgment than by guided care. The two linked 
studies did not look at the course of the patients’ depres-
sion, however, so we do not know how well the patients 
fared. Further analysis of general practitioners’ experi-
ence is therefore warranted for a more robust analysis 
of the QOF.
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Tocolytics and preterm labour
Whether to treat or not is the real dilemma, not which drug to use
Preterm labour is still the main cause of perinatal mor-
bidity and mortality in the developed world. Despite a 
better understanding of the pathophysiology, and the 
recognition that it is a syndrome with multiple causes, 
rates continue to rise.1 In the linked cohort study, de 
Heus and colleagues assess the incidence of serious 
maternal complications with the use of tocolytic drugs 
for the treatment of preterm labour.2 
Corticosteroids given to women at risk of preterm 
birth increase fetal lung maturity and can reduce fetal 
death, intraventricular haemorrhage, and respiratory dis-
tress by up to 50%.3 In contrast, it is still unclear whether 
tocolysis improves neonatal or longer term outcomes.4 
Thus, the Royal College of Obstetricians and Gynaecolo-
gists’ clinical guideline on tocolysis concludes that, “it is 
reasonable not to use tocolytic drugs.”5
Despite the lack of evidence, several tocolytic drugs 
are commonly used worldwide. They are used prima-
rily to delay delivery for up to 48 hours to allow for 
administration of corticosteroids or transfer to a unit 
with neonatal intensive care facilities (or both). Little 
consensus exists as to which tocolytic agent is the best. 
Beta agonists, atosiban, and indometacin all reduce 
the incidence of delivery within 48 hours compared 
with placebo, but none has been shown to improve 
neonatal outcomes.4 Nifedipine has not been studied 
in placebo controlled trials, but it is more effective at 
delaying delivery than β agonists, and has been associ-
ated with improved neonatal outcomes.6 Atosiban and 
nifedipine have not been directly compared.
The study by de Heus and colleagues assesses mater-
nal safety. They recorded adverse maternal effects in 
an unselected population of 1920 consecutive women 
given tocolytic drugs in routine clinical settings in the 
Netherlands and Belgium over an 18 month period. The 
most commonly used agent was atosiban (42%), followed 
by nifedipine (34%), β agonists (14%), and indometacin 
(8%).
The overall incidence of adverse effects was reassur-
ingly low, but the study highlights the dangers of multi-
drug regimens, which have no proven benefit either 
sequentially or in combination. Four women needed 
intensive care after being subjected to such regimens—
three of which included β agonists. But before such 
practices are condemned outright, a thorough analysis 
of each case is warranted, so that further research into 
safer combination treatments is not compromised.
Because of the definitions used in the study design, 
postpartum haemorrhage was not included as a mater-
nal adverse event. Some people may think this a sur-
prising omission considering the basic mechanism of 
action of all tocolytics.
Consistent with previous studies, the β agonists had 
a higher incidence of serious adverse drug reactions 
(1.7%) than nifedipine (0.9%); no such reactions were 
reported for atosiban.
Hypotension was the most serious adverse drug reac-
tion associated with nifedipine, which is not surprising 
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considering its licensed indication. Hypotension was 
defined as a systolic blood pressure of <100 mm Hg 
and a drop of more than 20%. Associated symptoms did 
not need to be treated. It is debatable whether this reac-
tion would be considered “life threatening” according to 
the Council for International Organizations for Medical 
Science definition used as a guideline in the article, and 
no justification is given for using these particular values. 
Indeed, the authors themselves question the importance 
of these events and point out that no associated episodes 
of fetal compromise occurred.
These findings highlight the relative maternal safety of 
tocolytics, although β agonists have the highest adverse 
event rate and their continued use is hard to justify. 
Atosiban stands out as the drug with the safest mater-
nal adverse event profile, but it has not been shown to 
improve neonatal outcomes and is considerably more 
expensive than nifedipine. Using the number needed 
to treat analysis provided in the article, we calculated 
that 108 patients would need to be treated with atosi-
ban to prevent one serious adverse drug reaction associ-
ated with nifedipine. This means that, allowing for the 
spread across the confidence intervals, an extra £30 000 
(€33 000; $44 000) to £45 000 would need to be spent 
for each serious adverse drug reaction prevented (costs 
sourced from British National Formulary, September 2008). 
Clearly a detailed cost-benefit analysis is warranted.
This study also serves as a timely reminder that the 
decision to use tocolysis should not be taken lightly, espe-
cially as we have no good test for differentiating “true” 
from “spurious” preterm labour, so many women are 
treated unnecessarily.4
After more than 30 years of research we still do not 
know whether tocolysis benefits the fetus, so the choice 
of which drug to use remains a secondary question. The 
real dilemma is whether or not we should treat at all. 
Not only may tocolysis lack any real benefit, but it could 
be harmful, as highlighted in the recent publication of 
the long term outcomes of the ORACLE II trial.7 In 
the original study, antibiotics were given to women with 
intact membranes who were at risk of preterm labour, 
and no improvement was seen in neonatal outcomes. But 
of major concern is the increased incidence of  cerebral 
palsy at 7 years seen in the recently published follow-up 
data.
We agree with de Heus and colleagues that a ran-
domised controlled trial of nifedipine and atosiban is 
needed; however, any such study should include a pla-
cebo arm. Accumulating evidence such as that from 
the ORACLE II trial and from groups examining the 
associations between infection, inflammation, preterm 
labour, and brain injury,8-11 alongside improvements 
in neonatal care, mean that the old assumption that 
“keeping the baby inside longer must be a good thing” 
can no longer go unchallenged.
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environmental waste in health care
must be reduced for the overall carbon reduction strategy to succeed
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In the linked analysis article, Hutchins and White 
describe an audit of anaesthetic waste collected from 
six theatres in one teaching hospital in the United 
Kingdom and identify potential improvements in 
the management of such waste.1 Around 540 kg of 
solid anaesthetic waste was produced (about 2300 kg 
per theatre per year), 40% of which was potentially 
recyclable paper, card, plastic, and glass. Analysis of 
five sharps bins found that only 4% by weight was 
true sharps waste (needles and broken glass)—57% 
was glass and 39% was “other” (packaging, plastic, 
metal, and fluid).
Last year’s World Health Assembly adopted a 
 powerful resolution on climate change, which not 
only warned of the stark consequences for human 
health but also identified how the health sector should 
respond to the profound changes taking place in the 
global ecosystem.2 The direct contribution of the health 
sector to environmental degradation is however less 
well  analysed and debated. It is clear that the scale of 
carbon reduction needed to limit the effects of global 
warming cannot be achieved without the health sector 
playing its part.
Analysis of the carbon footprint of the NHS in Eng-
land gave surprising results.3 About 18% of the NHS 
carbon footprint came from staff and patient travel, 
22% from energy usage, and 59% from procurement, 
including equipment and pharmaceuticals. This is 
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Managing research data for future use
the BmJ is now asking authors for data sharing statements
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For some time the BMJ has been watching other 
journals’ efforts to encourage authors to make raw 
research data available. Now we are taking part too, 
by asking authors to include a data sharing statement 
at the end of each original research article. The state-
ment will explain which additional data—if any—are 
available, to whom, and how. Those data could range 
from additional explanatory material to the complete 
dataset. People allowed access to the data might range 
from fellow researchers to everyone. And data might 
be available only on request, accessible online with a 
password, or openly accessible to all on the web with 
a link on bmj.com.
We understand that many authors wish to guard data 
until they have published all their own papers, and we 
know that data sharing is hard to do. But we hope that 
authors will, increasingly, set the data free, perhaps 
after a set period of personal use.
Data sharing means more than the open access pub-
lication of articles and the posting in online registries of 
unlikely to be an atypical finding, and in countries 
such as the Netherlands and Denmark, with a less car 
based transport system, the proportion attributable to 
procurement may be higher.
To tackle the problem, medical industries will need 
to review their processes and supply chains and adapt 
their purchasing approaches to make carbon reduc-
tion a priority. In some areas of health care, such as 
pharmaceuticals, the avoidance of unnecessary pre-
scribing or treatment will help. But in other areas, 
including where single use devices are common, 
reducing, reusing, reprocessing, and recycling waste 
will cause intense debate.
The World Health Organization estimates that 20% 
of the total waste arising from healthcare activities is 
potentially hazardous.4 Concerns about transmission 
of agents such as the prion responsible for variant 
Creutzfeldt-Jakob disease and viruses that can spread 
via body fluids have driven much of the recent growth 
in single use equipment and the consequent increase 
in waste classified as potentially hazardous. However, 
evidence shows that items intended for single use are 
often reused without sterilisation.4
The WHO reports that worldwide about 16 mil-
lion hepatitis B infections, 4 million hepatitis C infec-
tions, and 160 000 HIV infections occur annually from 
improper reuse of syringe needles.4 Concern about 
injecting practices has led some countries to advocate 
a shift back to reusable glass syringes. From the per-
spective of carbon reduction, the importance of tack-
ling the volume of clinical waste is reinforced by the 
estimated high fossil carbon content of clinical waste 
compared with general municipal waste.5
The importance of reducing healthcare waste is 
heightened by the steadily reducing landfill capac-
ity in many countries and the sometimes vocifer-
ous opposition to the construction of incineration 
plants. Healthcare systems need to embrace a holis-
tic approach to minimising waste but also encour-
age commitment and innovation among healthcare 
professionals in  individual specialties. Hutchins and 
White’s audit of waste is an example of how health-
care professionals can take into account the envi-
ronmental consequences of their work and minimise 
the amount of clinical waste while recognising that 
patient safety is paramount.1 Their approach is valu-
able and would make a substantial contribution if it 
became the norm. To be fully effective it must how-
ever be linked to rigorous procurement practices that 
have environmental concerns at their heart. If they 
operate in an organised manner, clinicians are well 
placed to become environmentally discerning cus-
tomers and demand clinical supplies that are much 
less wasteful.
Healthcare professionals are no different from other 
members of society, and many are making the neces-
sary changes in their homes to reduce their ecological 
footprint. They should be encouraged to bring the 
same concerns into play in their professional lives. 
Thomas Berry, the American theologian, has said that 
you cannot have well humans on a sick planet.6 The 
goals of healing people and healing the planet will 
increasingly need to go hand in hand.
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Sharing medical research data: ethical and editorial 
barriers and proposed solutions11
Ethics committees: encourage researchers to include plans to publish 
data in trial information sheets and discuss the safeguards in place to 
protect the privacy of patients
Research funding agencies: give greater scrutiny to data sharing plans 
and monitor their enforcement
Journal editors and publishers: recommend that authors prepare data 
in line with an agreed standard (which requires further consideration). 
Encourage deposition of data in the journal or suitable third party 
repository as part of the submission process, potentially via an 
accession number system, as for trial registration
Trialists: obtain explicit consent for publication of suitably anonymised 
raw data as part of patient recruitment procedures
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study protocols and main results. Sharing allows other 
researchers—and perhaps scientists, clinicians, and 
patients—access to raw numbers, analyses, facts, ideas, 
and images that do not make it into published articles 
and registries. At its fullest extent, data sharing means 
free access for everyone. Many people would call this 
a moral obligation because most research is publicly 
funded and involves the public as participants. Other 
potential benefits include quicker scientific discovery 
and learning, better understanding of research meth-
ods and results, more transparency about the quality 
of research, and greater ability to confirm or refute 
research through replication.
Such sharing raises important questions about who 
owns the data,1 who gives permission to release the 
data (including funders, research participants, owners 
of the intellectual property, and copyright holders), 
where and how the data should be stored (in electronic 
repositories managed locally, nationally, or interna-
tionally; or in subject specific databases), how the data 
should be stored and managed and made compatible 
across repositories, how the data should be accessed 
and mined, who should have access and when, and 
what limits may be needed to prevent misuse and 
mishandling of data. Yet, despite these and other com-
plexities, the movement to free the world’s vast swathes 
of untapped research data is gathering speed.
This momentum is coming not just from a few open 
access advocates and proponents of making the web a 
searchable network of data as well as articles.2 As del-
egates at the UK Research Data Service (UKRDS) con-
ference in London heard last month, many researchers 
would also like access to unpublished raw data.3 Yet 
academic, technology, publishing, and business inter-
ests currently conspire—deliberately or not—to keep 
data hidden away. Researchers lack the incentives and 
the means to analyse all the data that they generate, to 
manage data after funded projects have ended, and to 
share data other than informally with certain collabora-
tors. A recent UKRDS study on the logistics and costs 
of developing and maintaining a national shared digital 
research data service concluded that such a service is 
feasible and worth funding, and that it could greatly 
increase UK universities’ potential for research and 
innovation and their global competitiveness.4 Mean-
while, many other countries are already on the case.
Data sharing is hardly a new idea. Physicists, envi-
ronmentalists, and researchers in the basic biomedical 
sciences have been doing this for years. Funders such 
as the UK Medical Research Council,5 US National 
Institutes of Health,6 and Wellcome Trust7 already 
mandate sharing of data from research in basic  science 
and genetics. The US National Heart, Lung, and 
Blood Institute has opened up to researchers world-
wide its collection of genetic and clinical data from 
three asthma research networks and the Framingham 
Heart Study.8 Even GlaxoSmithKline has opened 
up its “patent pool” so that data relevant to finding 
drugs for neglected diseases can be explored by other 
 researchers.9
Numerous science journals mandate data sharing 
too. For example, a condition of publication in a Nature 
journal is that “authors are required to make materials, 
data and associated protocols promptly available to 
others without preconditions. Data sets must be made 
freely available to readers from the date of publication, 
and must be provided to editors and peer-reviewers at 
submission, for the purposes of evaluating the manu-
script. For the following types of data set, submission 
to a community-endorsed, public repository is manda-
tory.”10 These data sets include those containing DNA 
and protein sequences, macromolecular structures, 
microarray data, and chemical compound screening.
For most medical journals, however, sharing of clini-
cal research data is a new and difficult concept. Last 
week the editors of the open access BioMed Central 
journal Trials spelled out the main ethical and edito-
rial barriers to data sharing in medicine and, partly 
drawing on discussions with scientists and other edi-
tors (including TG), proposed some solutions (box). 11 
The maintenance of patient confidentiality is a major 
challenge, because the combination of clinical data and 
personal data and the place of research can be enough 
to reveal a research participant’s identity. Hence clini-
cal research data need to be anonymised carefully 
before sharing and, if a risk of identification remains, 
patients should be asked for consent to data sharing as 
well as consent to taking part in the research.
Since 2007, the Annals of Internal Medicine has been 
asking authors to make a “reproducible research state-
ment” at the end of each research paper.12 Authors 
state whether and within what limits they will share 
the original study protocol, the dataset used for the 
analysis, and the computer code used to produce the 
results. We gladly acknowledge that we are emulat-
ing this policy in introducing data sharing statements 
for BMJ research articles and bringing data sharing to 
authors’ and readers’ attention. We hope authors and 
readers will now join us in this debate and will help 
journals to set data free.
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